Marty was named President and CEO of Mersana in 2023, bringing to the company extensive drug development experience and demonstrated leadership capabilities across both small and large biopharmaceutical organizations. He also has been a member of Mersana’s Board of Directors since 2020.

Prior to his CEO role at Mersana, Marty most recently served as President, Head of R&D and, prior to that, as Chief Medical Officer, at Xilio Therapeutics, Inc. Before joining Xilio, he served as Chief Medical Officer at TESARO, Inc., and after TESARO’s acquisition by GlaxoSmithKline plc, as Senior Vice President, Clinical. Earlier, Marty served as Vice President, Oncology Clinical Research at Merck Research Laboratories and in roles of increasing responsibility in the areas of oncology clinical development, drug safety and pharmacovigilance at Schering-Plough, Hoffmann-La Roche and Rhone-Poulenc Rorer. His work has contributed to the approval of such oncology medicines as docetaxel, dostarlimab, niraparib, pembrolizumab and trastuzumab.

Marty began his career as an Assistant Professor of Oncology at the University of Texas M.D. Anderson Cancer Center. He received his medical degree from Baylor College of Medicine.

Fun fact about Marty: While many biotech executives have had to dust themselves off and get back in the saddle following a setback, Marty literally once did so after getting tossed off his horse during a cattle round-up.